Despite a 15% drop in the SPDR S&P Biotech ETF, insider buying presents opportunities. Read why these small and mid-cap ...

The biotech scene can be seen as fairly risky for new investors who want to put money to work. After all, it’s really tough ...

If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the Invesco Biotechnology & Genome ETF (PBE), a passively managed exchange traded ...

Sana is a gene and cell therapy clinical-stage biotech firm and a penny stock that has fallen by 48.5% in the year leading to January 17, 2025. What may set this company apart from a host of similar ...

You should consider the VanEck Biotech ETF (BBH), a passively managed exchange traded fund launched on 12/20/2011. Passively managed ETFs are becoming increasingly popular with institutional as ...

Launched on 06/23/2005, the Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market. What Are Smart ...

With morale at a low point, biotech and pharma CEOs are cautiously optimistic about the incoming Trump administration.

The Fund seeks to replicate as closely as possible the performance of an index derived from the biotechnology segment of a U.S. total market composite index. The Fund uses a passive management ...

iShares Biotechnology ETF earns an Average Process Pillar rating. Morningstar's algorithmically assigned Passive Process ratings are first formulated by comparing the historical efficacy of ...